Ekso Bionics Q1 2025 revenue $3.4M, net loss $2.9M; partnerships expand distribution

EKSO BIONICS HOLDINGS, INC.

2025-Q1 EPS reported -$0.12 revenue$3,375,000

Revenue of $3.4M down 11% YoY ($3.8M); net loss $2.9M ($0.12/sh) vs $3.4M ($0.20/sh) in Q1 2024.
Gross margin improved to 53.5% from 51.9%; cash used in operations fell 43% to $2.0M.
Named National Seating & Mobility as exclusive U.S. CRT distributor for Ekso Indego Personal.
Appointed Bionic Prosthetics & Orthotics Group as first O&P distributor for Ekso Indego Personal.
Cash and restricted cash $8.1M at March 31, 2025; $3.8M net proceeds from warrant exercises.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.